ScienceNot yet confirmed elsewhere1 publisher2 min readPublished
Mebendazole extends gefitinib's effect on resistant lung tumours in mice
Researchers pairing the deworming drug mebendazole with gefitinib report a median tumour doubling time of 25 days in mice, against 15.5 for gefitinib alone. The data come from one resistant EGFR-mutant model, and the tumours were not eliminated.
The Scientist · Science desk
Median tumour doubling time in mice: 25 days with gefitinib and mebendazole together, 15.5 days with gefitinib alone, 10.3 days with mebendazole alone and 6.2 days without treatment.
| Figure | Value | Note | Claim |
|---|---|---|---|
| Tumour doubling time, both drugs | 25 days, median | 11 | |
| Gefitinib alone | 15.5 days, median | 10 | |
| Mebendazole alone | 10.3 days, median | 9 | |
| No treatment | 6.2 days, median | 8 |
What happened
- After 72 hours in resistant human cells, the combination left viability at about 38 percent of control, against roughly 93 percent for gefitinib alone and 80 percent for a low dose of mebendazole.
- In the 40-day mouse study, with eight animals per group, untreated tumours doubled in a median of 6.2 days and mebendazole alone stretched that to 10.3.
- Cell tests also found DNA damage, including single- and double-strand breaks, which the researchers read as consistent with stress from copying DNA.
Why it matters
- constraint Mebendazole is absorbed variably after swallowing, so the exposure and dose a patient would need are unsettled.
- exposure Safety is untested: no sustained weight loss in mice does not establish it, and organ, healthy-tissue, prolonged-use and drug-interaction experiments remain to be done.
- decision The researchers list additional resistant cell lines and patient-derived tumour models as priorities, so any claim beyond this one model waits on them.
Take what each drug did alone and ask what two independent effects would give. In the dish, gefitinib and a low dose of mebendazole would leave viability near 74 percent, from 0.93 times 0.80 [19]. The measured figure was about 38 percent [3].
The mouse data do not show the same gap. Gefitinib alone lengthened the median doubling time 2.5-fold [20], and mebendazole alone about 1.66-fold [21]. Multiplied, that predicts a combined doubling time of roughly 25.8 days [22]. The combination gave 25 [11]. On that scale the animal result is about what two independent effects would produce. The authors did not formally quantify drug synergy [13], so both checks here are rough comparisons of ours, not the paper's analysis.
"Our findings suggest that the combination does more than simply add another source of damage, but we cannot yet say conclusively that it fully restores sensitivity to gefitinib," said Shakta Mani Satyam [14], a pharmacology researcher at RAK Medical and Health Sciences University in the United Arab Emirates [18].
The dish data also carry a dose message. A fivefold higher concentration of mebendazole alone brought viability to around 30 percent [4], 8 points below the combination [23]. The paper describes the two reductions as comparable [5]. Adding gefitinib to the lower dose therefore gets close to what the higher mebendazole dose does alone. If a swallowed dose can reach the higher concentration, the dish data do not show that gefitinib is needed. If it cannot, the lower-dose combination is the comparison that matters.
Resistance in this model did not mean gefitinib did nothing in the animal. In the dish, gefitinib alone left viability near the control level [3]. In mice carrying tumours grown from the resistant human cells, it still lengthened doubling time 2.5-fold over the untreated 6.2 days [c7, c8, d2]. One readout is a 72-hour viability count and the other a doubling time across 40 days, so they are not interchangeable.
The figures here are from ScienceAlert's account of the PLOS ONE paper. That account gives medians from eight mice per group without intervals [7].
What to watch
- Results in additional gefitinib-resistant cell lines and patient-derived tumour models, which would test whether the effect extends past this single model.
- Whether the combination holds against osimertinib-resistant cells, the question Satyam called important.
- A formal synergy analysis, and exposure data showing whether an oral mebendazole dose reaches the concentration that worked alone in the dish.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence40
- Adoption
- Insufficient
- Hype gap+20
- Incentives
- Insufficient
- Confidence50
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
The study, published in PLOS ONE, paired gefitinib, a targeted cancer treatment, with mebendazole, a medicine used against parasitic worm infections.
- [2]
The study focused on one model of EGFR-mutant non-small cell lung cancer that had become resistant to gefitinib.
- [3]
In resistant human lung cancer cells after 72 hours, viability with gefitinib alone remained at about 93 percent of the untreated control level, a low concentration of mebendazole alone lowered it to approximately 80 percent, and the combination brought it to about 38 percent.
- [4]
A fivefold higher concentration of mebendazole alone reduced cell viability to around 30 percent.
- [5]
The combination with the lower mebendazole concentration produced a reduction comparable to that of the higher concentration alone, according to the paper.
- [6]
In the cell experiments, tests detected DNA damage, including breaks in one or both strands, which the researchers interpret as consistent with increased stress associated with copying DNA.
- [7]
The mouse experiment ran 40 days with eight mice per treatment group, using tumours grown from the resistant human cells.
- [8]
In the mouse study, the median time for tumours to double in size was 6.2 days without treatment.
- [9]
Mebendazole alone extended the median tumour doubling time to 10.3 days.
- [10]
Gefitinib alone extended the median tumour doubling time to 15.5 days.
- [11]
With both drugs, the median tumour doubling time reached 25 days.
- [12]
The tumours were not eliminated, and the findings are preclinical; results from one resistant cancer model cannot establish how other lung cancers would respond.
- [13]
The researchers cannot yet determine whether mebendazole reverses resistance to gefitinib or adds damage that makes resistant cells less able to survive, and they did not formally quantify drug synergy or directly track how the DNA-copying machinery failed.
- [14]
Our findings suggest that the combination does more than simply add another source of damage, but we cannot yet say conclusively that it fully restores sensitivity to gefitinib,
- [15]
Mebendazole's absorption after swallowing can vary, so effective drug exposure and dosing need further investigation.
- [16]
The mice showed no sustained body-weight loss, but that alone cannot establish safety; further experiments must examine effects on organs and healthy tissues, prolonged use, and interactions between the medicines.
- [17]
Additional resistant cell lines and patient-derived tumour models are research priorities, and Satyam said resistance to osimertinib, a newer EGFR-targeted treatment, is an important question for future research.
- [18]
Shakta Mani Satyam is a pharmacology researcher at RAK Medical and Health Sciences University in the United Arab Emirates.
- [19]
If gefitinib (about 93 percent viability) and low-dose mebendazole (about 80 percent) acted independently, expected combined viability is about 74 percent.
- [20]
Gefitinib alone lengthened the median tumour doubling time 2.5-fold relative to no treatment.
- [21]
Mebendazole alone lengthened the median tumour doubling time about 1.66-fold relative to no treatment.
- [22]
Multiplying the two single-drug fold changes predicts a combined median doubling time of roughly 25.8 days, against 25 days observed.
- [23]
Viability with the lower mebendazole dose plus gefitinib (about 38 percent) was 8 percentage points above that with the fivefold higher mebendazole dose alone (about 30 percent).
Sources
1 independent publisher whose own reporting we read for this story.
- sciencealert.comA Cheap Deworming Pill Could Help Beat Drug-Resistant Lung Cancer
1 article · October 12, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
- Lung cancer researchFollow
- Targeted therapy resistanceFollow
- Drug RepurposingFollow